Rivermark
Developer of medical device for treatment of benign prostatic hyperplasia
📍 Milwaukee, United States · Genitourinary Disorders
Funding snapshot
Last roundSeries D
Amount$20M
Date13 May 2026
About
Developer of medical device for treatment of benign prostatic hyperplasia. It offers minimally invasive device FloStent which consist of a nitinol stent that holds the prostatic urethra open to restore normal urinary function.
Latest news
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer
ImmunoACT
Developer of cell and gene therapies for cancer treatment
HaystackAnalytics
Provider of genomics technology for personalized clinical decisions
4baseCare
Provider of precision oncology solutions, including genomic testing and digital health